Abstracts tagged "T-Regulatory Cells"

Abstract Number: 2908 • 2014 ACR/ARHP Annual Meeting
Flip Deficiency in Dendritic Cells Promotes Spontaneous Arthritis Mediated By Reduced Treg and Increased Autoreactive CD4⁺t Cells
Qiquan Huang¹, Harris R. Perlman², Robert Birkett³, Renee E. Doyle⁴, Deyu Fang⁵, G Kenneth.Haines⁶, William H. Robinson⁷, Syamal K. Datta⁸, Hyewon Phee⁹ and Richard M. Pope¹⁰, ¹Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Division of Rheumatology, Department od Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Mount Sinai Hospital School of Medicine, New York, New York, NY, ⁷VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁸Rheumatology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL
Background/Purpose Flip (CFLAR) has been identified as a rheumatoid arthritis (RA) risk allele and is important in preventing death receptor mediated apoptosis of dendritic cells…
Abstract Number: 2347 • 2014 ACR/ARHP Annual Meeting
Therapeutic Effect of a Novel Histone Deacetylase 6 Inhibitor, CKD-L, on Collagen Induced Arthritis and Peripheral Blood Mononuclear Cells from Patients with Rheumatoid Arthritis
Bo Ram Oh¹, Hyojin Lim², Daekwon Bae², Nina Ha², Young il Choi², Hyun Jung Yoo^3,4, Jin Kyun Park³, Eun Young Lee⁵, Eun Bong Lee³ and Yeong Wook Song^3,4, ¹Division of Rheumatology, Department of Molecular Medicine and Biophamaceutical Sciences, BK 21 plus Graduate School of Convergence Science Technology, Colleage of Medicine, Seoul National University, Seoul, South Korea, ²Department of Pharmacology and Toxicology, CKD Research Institute, CKD Pharmaceutical Company, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ⁴Department of Molecular Medicine and Biophamaceutical Sciences, BK 21 plus Graduate School of Convergence Science Technology, Colleage of Medicine, Seoul National University, Seoul, South Korea, ⁵Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose Epigenetic regulation plays an important role in inflammatory arthritis, including rheumatoid arthritis (RA). Histone deacetylase inhibitor (HDACi) has been recently reported to have therapeutic…
Abstract Number: 2164 • 2014 ACR/ARHP Annual Meeting
Self-Phospholipids Regulate Inflammation Via Activation of CD1d-Restricted T-cells and Induction of ‘anti-inflammatory’ Myeloid-Derived Suppressor Cells (MDSC)
Ram Raj Singh^1,2,3,4, Cynthia Tran¹, Priti Prasad¹, Jing Wang⁵, Dirk Zajonc⁵ and Ramesh Halder¹, ¹Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, UCLA, Los Angeles, CA, ²Interdepartmental Program in Molecular Toxicology, UCLA, Los Angeles, CA, ³Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, ⁴Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA, ⁵La Jolla Institute of Allergy and Immunology, La Jolla, CA
Background/Purpose Self-lipids play an increasingly appreciated role in immunity and inflammation. Lipid antigens are presented by CD1d and CD1a-d molecules in mouse and human, respectively,…
Abstract Number: 1799 • 2014 ACR/ARHP Annual Meeting
Elevated Indoleamine-2,3-Dioxygenase (IDO) Activity and Kynurinene-3-Monooxygenase (KMO) Expression in Interferon Positive Primary Sjogrens Syndrome Patients Is Associated with Increased CD25^hiFoxP3⁺regulatory Tcells: A Skew Towards Neurotoxicity or an Attempt to Rescue?
Naomi I Maria¹, Cornelia G. van Helden-Meeuwsen¹, Zana Brkic¹, Sandra M.J. Paulissen^1,2, Virgil A. Dalm¹, Paul L. van Daele¹, P. Martin van Hagen¹, Sinead M. Gibney^1,3, Andrew Harkin³, Hemmo A. Drexhage¹, Erik Lubberts^1,2 and Marjan A. Versnel¹, ¹Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ²Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands, ³Trinity College Institute of Neuroscience, Neuropsychopharmacology, Dublin, Ireland
Background/Purpose: A role for indoleamine-2,3-dioxygenase (IDO) in suppression of effector T-cell function and promotion of regulatory T-cell (Treg) differentiation has been described. IDO - the…
Abstract Number: 1750 • 2014 ACR/ARHP Annual Meeting
The Effect of a Pro-Inflammatory Milieu on Tregalizumab (BT-061)-Induced Regulatory T-Cell Activity
Jan Kubach¹, Faiza Rharbaoui², Martin Koenig², Jörg Schüttrumpf², Silke Aigner², Benjamin Dälken² and Helmut Jonuleit¹, ¹Department of Dermatology, University of Mainz Medical Center, Mainz, Germany, ²Biotest AG, Dreieich, Germany
Background/Purpose Regulatory T cells (Tregs) are essential for maintaining normal immune homeostasis. We have previously reported that tregalizumab is a humanized, non-depleting, CD4 agonistic antibody…
Abstract Number: 1737 • 2014 ACR/ARHP Annual Meeting
Altered Phenotype and Function of Senescent Regulatory T Cells in Rheumatoid Arthritis
Johannes Fessler¹, Chrsitine Schwarz¹, Anja C. Ficjan¹, Rusmir Husic², Evelyne Höller³, Angelika Lackner¹, Winfried B. Graninger⁴ and Christian Dejaco^1,5, ¹Rheumatology and Immunology, Medical University Graz, Graz, Austria, ²Rheumatology, Medical University Graz, Graz, Austria, ³Endocrinology, Medical University Graz, Graz, Austria, ⁴Internal medicine/Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁵Department of Rheumatology and Immunology, Medical University Graz, Graz A-8036, Austria
Background/Purpose Immunosenescence accompanied by accumulation of senescent T cells is a hallmark feature in the pathogenesis of rheumatoid arthritis (RA). Here we characterize a novel senescent…
Abstract Number: 1732 • 2014 ACR/ARHP Annual Meeting
Attenuation of Sclerodermatous Graft Versus Host Disease (sclGVHD) in IL4RA Receptor-Deficient Mice
Katia Urso¹, Kelly Tsang², Robert Lafyatis³ and Antonios O. Aliprantis², ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose Scleroderma is a rare autoimmune disease characterized by the accumulation of fibrotic tissue in multiple organs including the skin, gut and lungs. To date,…
Abstract Number: 1642 • 2014 ACR/ARHP Annual Meeting
A Prospective Study of Vitamin D Effects on T Cells Phenotype in Patients with Systemic Lupus Erythematosus Treated with Different Regimens of Supplementation for Two Years
Silvia Piantoni, Laura Andreoli, Alessandra Zanola, Francesca Dall'Ara, Mirko Scarsi and Angela Tincani, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose Vitamin D (VD) receptor is constitutively expressed on the membrane of multiple cells, including lymphocytes. Recent studies highlight that VD may have an action…
Abstract Number: 1455 • 2014 ACR/ARHP Annual Meeting
Ex Vivo-Expanded, but Not in Vitro-Induced, Human Regulatory T Cells Are Suitable for Cell Therapy in Rheumatological Autoimmune Diseases Thanks to Stable FOXP3 Demethylation
Maura Rossetti¹, Roberto Spreafico¹, Maryam Moshref², Jorg van Loosdregt³ and Salvatore Albani¹, ¹SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Duke-NUS Graduate Medical School, Translational Research Unit, Sanford-Burnham Medical Research Institute, Singapore, Singapore, ²Translational Research Unit, Sanford-Burnham Medical Research Institute, La Jolla, CA, ³Translational Research Unit, Sanford-Burnham Medical Research Institute, San Diego, CA
Background/Purpose: Treg cell therapy is a promising approach for transplant rejection and severe autoimmunity. Unfortunately, sufficient Treg numbers can be obtained only upon in vitroculture. Functional…
Abstract Number: 618 • 2014 ACR/ARHP Annual Meeting
A Gender Bias in Gut Microbiota of SKG Mice Colonized with a Limited Bacterial Consortium Associated with Severity of Spondyloarthritis and Ileitis Triggered By Beta-Glucan
Linda Rehaume, Olga Zbarskaya, Alicia Kang, Helen Benham, Paraic O Cuiv, Mark Morrison and Ranjeny Thomas, University of Queensland Diamantina Institute, Brisbane, Australia
Background/Purpose Beta-glucan (curdlan)-treated BALB/c ZAP-70W163C(SKG) mutant mice develop IL-23-dependent spondyloarthritis, and curdlan promotes ileitis in SKG mice housed under specific pathogen-free (SPF) but not germ-free…
Abstract Number: 2215 • 2013 ACR/ARHP Annual Meeting
Apoptotic Cell-Based Therapy To Treat Collagen-Induced Experimental Arthritis. Rationale For The Use Of Apoptotic Cells In The Treatment Of Rheumatoid Arthritis
Sylvain Perruche¹, Amandine Clauzon¹, Francis Bonnefoy¹, Eric Toussirot² and Philippe Saas³, ¹UMR1098 INSERM, EFS Bourgogne Franche Comté, Besançon, France, ²Université de Franche Comté , CHRU, CIC Biotherapy 506 and Rheumatology and EA 4266 Pathogens and Inflammation, Besançon, France, ³Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France
Background/Purpose: Most of the currently available biological agents used in the treatment of rheumatoid arthritis (RA) target a cellular or soluble factor involved in the…
Abstract Number: 1643 • 2013 ACR/ARHP Annual Meeting
Ex Vivo Suppression Of RA Effector T Cells (Teff) By Mapc Media Is Synergistic With Treg
Gali Malul¹, David Soler², Donald D. Anthony³, Hillard M. Lazarus⁴, Nicholas Lehman⁵, Thomas McCormick², Julia M. Sugalski⁶, Anthony E. Ting⁵ and Nora G. Singer⁷, ¹Rheumatology, MetroHealth Medical Center, Cleveland, OH, ²Dermatology, Case Medical Center, Cleveland, OH, ³Medicine, Case Western Reserve University, Cleveland, OH, ⁴Comprehensive Cancer Center, Case Medical Center, Cleveland, OH, ⁵Athersys, Inc., Cleveland, OH, ⁶Medicine/infectious disease, Case Western Reserve University, Cleveland, OH, ⁷Medicine, Division of Rheumatology, MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Use of mesenchymal/multipotent stem cells (MSCs/MAPCs) is an emerging immune modulatory therapeutic strategy promising for a number of human diseases. Multipotent adult progenitor cells…
Abstract Number: 1641 • 2013 ACR/ARHP Annual Meeting
Bispecific Antibodies For Redirection Of Human Regulatory T Cells To Surface-Inducible Autoantigen La/SS-B
Stefanie Koristka¹, Marc Cartellieri², Claudia Arndt², Anja Feldmann², Irene Michalk², Claudia C. Bippes², Nicole Berndt², Anne Hermsdorf², Slava Stamova², Biji T. Kurien³, Robert Hal Scofield⁴, A. Darise Farris⁵, Judith A. James⁶, Holger Bartsch⁷ and Michael Bachmann², ¹Carl Gustav Carus TU-Dresden, Dresden, Germany, ²Inst. Immunology, Carl Gustav Carus TU-Dresden, Dresden, Germany, ³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁵Arthritis & Immunology Program, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Inst. Immunol., Carl Gustav Carus TU-Dresden, Dresden, Germany
Background/Purpose: Adoptive transfer of regulatory T cells (Tregs) represents a promising strategy for treatment of auto- and alloimmunity. However, it is difficult to obtain therapeutically…
Abstract Number: 1412 • 2013 ACR/ARHP Annual Meeting
Use Of a Biologic Marker For An Integrated Pharmacodynamic and Clinical Analysis To Inform Further Clinical Development, Including Dose Selection For The Phase 2b Trial – Treat 2b – Of Tregalizumab In Rheumatoid Arthritis
Eva Dokoupilova¹, Slawomir Jeka², Jiri Vencovsky³, Janusz Badurski⁴, Klaas Prins⁵, Vibeke Strand⁶, Edward C. Keystone⁷, Ronald F van Vollenhoven⁸, Jurgen Wollenhaupt⁹, Andrea Wartenberg-Demand¹⁰, Gabriele Niemann¹⁰, Ahmed Abufarag¹⁰, Silke Aigner¹⁰, Sibylle Kaiser¹⁰, Faiza Rharbaoui¹⁰, Niklas Czeloth¹¹, Ralf Wolter¹⁰, Benjamin Dälken¹⁰ and Thorsten Holzkämper¹⁰, ¹Medical Plus s.r.o, Uherske Hradiste, Czech Republic, ²Clinic of Rheumatology and Connective Tissue Diseases University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Torun, Bydgoszcz, Poland, ³Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Center of Osteoporosis and Osteo-articular Diseases, Bialystock, Poland, ⁵qPharmetra, Nijmegen, Netherlands, ⁶Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ⁷Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁸ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ¹⁰Biotest AG, Dreieich, Germany, ¹¹Global Research Immunology, Biotest AG, Dreieich, Germany
Background/Purpose: In patients with rheumatoid arthritis (RA) reduced numbers and functional impairment of regulatory T cells (Tregs) have been observed. Tregalizumab is a humanized, agonistic…
Abstract Number: 719 • 2013 ACR/ARHP Annual Meeting
Mammalian Target Of Rapamycin (mTOR) Skews T Cell Lineage Development In Systemic Lupus Erythematosus (SLE)
Hiroshi Kato¹ and Andras Perl², ¹Internal Medicine, Division of Rheumatology, SUNY Upstate Medical University, Syracuse, NY, ²Dept of Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: mTOR activity is increased in SLE T cells and its blockade has therapeutic efficacy in SLE. Murine studies showed essential roles of mTORC1 in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.